Graduate Program in Genetics, Tufts Graduate School of Biomedical Sciences, Boston, MA 02111, USA
Joseph Sarhan
Medical Scientist Training Program (MSTP), Tufts University School of Medicine, Boston, MA 02111, USA; Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, MA 02111, USA
Beiyun C. Liu
Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN 38104, USA
Wilson M. Connolly
Department of Immunology, Tufts University School of Medicine, Boston, MA 02111, USA
Stephen A. Schworer
Allergy and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA
Irina Smirnova
Department of Immunology, Tufts University School of Medicine, Boston, MA 02111, USA
Amy Y. Tang
Department of Immunology, Tufts University School of Medicine, Boston, MA 02111, USA
Vladimir Ilyukha
Petrozavodsk State University, Petrozavodsk, Republic of Karelia 185910, Russia
Jodie Pietruska
Department of Cell, Molecular & Developmental Biology, Tufts University School of Medicine, Boston, MA 02111, USA
Soroush Tahmasebi
Department of Biochemistry, Goodman Cancer Research Center McGill University, Montreal, QC H3A 1A3, Canada
Nahum Sonenberg
Department of Biochemistry, Goodman Cancer Research Center McGill University, Montreal, QC H3A 1A3, Canada
Alexei Degterev
Department of Cell, Molecular & Developmental Biology, Tufts University School of Medicine, Boston, MA 02111, USA
Alexander Poltorak
Department of Immunology, Tufts University School of Medicine, Boston, MA 02111, USA; Petrozavodsk State University, Petrozavodsk, Republic of Karelia 185910, Russia; Corresponding author
Summary: Receptor-interacting protein kinase 1 (RIPK1) and 3 (RIPK3) are well known for their capacity to drive necroptosis via mixed-lineage kinase-like domain (MLKL). Recently, RIPK1/3 kinase activity has been shown to drive inflammation via activation of MAPK signaling. However, the regulatory mechanisms underlying this kinase-dependent cytokine production remain poorly understood. In the present study, we establish that the kinase activity of RIPK1/3 regulates cytokine translation in mouse and human macrophages. Furthermore, we show that this inflammatory response is downregulated by type I interferon (IFN) signaling, independent of type I IFN-promoted cell death. Specifically, low-level constitutive IFN signaling attenuates RIPK-driven activation of cap-dependent translation initiation pathway components AKT, mTORC1, 4E-BP and eIF4E, while promoting RIPK-dependent cell death. Altogether, these data characterize constitutive IFN signaling as a regulator of RIPK-dependent inflammation and establish cap-dependent translation as a crucial checkpoint in the regulation of cytokine production. : Balancing inflammatory responses is critical for host survival. Muendlein et al. show that constitutive type I IFN signaling inhibits translation machinery activated downstream of the kinase activity of RIPK1/3, preventing the production of a subset of inflammatory cytokines. This work identifies cap-dependent translation as a checkpoint in regulation of RIPK1/3-kinase-dependent inflammation. Keywords: inflammation, necroptosis, constitutive IFN, translation, macrophage, receptor-interacting protein kinases